Tuberculosis alters pancreatic enzymes in the absence of pancreatitis

African Journal of Laboratory Medicine

 
 
Field Value
 
Title Tuberculosis alters pancreatic enzymes in the absence of pancreatitis
 
Creator Motswaledi, Modisa S. Sekgwama, Rosinah Kasvosve, Ishmael
 
Subject gastroenterology; clinical chemistry; Amylase, lipase, tuberculosis, erythrocyte sedimentation rate (ESR), hemoglobin (HB), treatment duration.
Description Background: Lipases and phospholipases are thought to contribute to the pathogenesis of Mycobacterium tuberculosis (MTB) infection. Genes coding for lipases, phospholipases and amylase are present in MTB, enabling the bacteria to produce these enzymes.Objective: To compare serum lipase and amylase activity levels in patients with tuberculosis (TB) against those of healthy controls.Methods: Serum lipase and amylase activity levels were measured in 99 patients and 143 healthy controls using the Vitros 250 Chemistry analyser. Reference ranges for serum lipase and amylase were 23–300 U/L and 30–110 U/L, respectively.Results: Lipase was higher in patients with MTB than in controls (81.5 IU/L versus 66.5 IU/L, p = 0.006). Similarly, amylase was higher in the MTB patient group (76 IU/L versus 60 IU/L, p 0.001). The Pearson correlation coefficient for lipase versus amylase (R) was higher in the controls (R = 0.351, p 0.0001) compared with MTB patients (R = 0.217, p = 0.035). Amongst MTB patients, lipase activity correlated positively with erythrocyte sedimentation rate (ESR) (R = 0.263, p = 0.013), but not with haemoglobin concentration or treatment duration. A weak inverse correlation was noted between ESR and treatment duration (R = -0.222, p = 0.028).Conclusion: Pancreatic enzyme levels differ between MTB patients and normal controls; however, this difference still lies within the normal range. The concomitant increase of lipase with ESR, an inflammatory marker, could conceivably suggest a causal relationship. Further research is necessary to characterise MTB-derived enzymes for diagnostic and therapeutic utility.
 
Publisher AOSIS
 
Contributor Botswana Ministry of Health
Date 2014-10-16
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — case control
Format text/html application/octet-stream text/xml application/pdf
Identifier 10.4102/ajlm.v3i1.129
 
Source African Journal of Laboratory Medicine; Vol 3, No 1 (2014); 5 pages 2225-2010 2225-2002
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://ajlmonline.org/index.php/ajlm/article/view/129/228 https://ajlmonline.org/index.php/ajlm/article/view/129/229 https://ajlmonline.org/index.php/ajlm/article/view/129/230 https://ajlmonline.org/index.php/ajlm/article/view/129/208
 
Coverage — — —
Rights Copyright (c) 2014 Modisa S. Motswaledi, Rosinah Sekgwama, Ishmael Kasvosve https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT